Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling)
Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup).
3 findings from 1 review
Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in participants with one or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Harms: adverse events (poorly assessed and reported) · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events or complications of treatment
1 finding from 1 review
Discontinuation of medication due to adverse events · older people with normal cognitiona
Statins showed no clear difference in adverse events leading to discontinuation of therapy compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Adverse drug events · people with ADHD and epilepsy
1 finding from 1 review
Adverse events (all adverse events) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (excluding deaths) at 26 weeks · vascular dementia and other vascular cognitive impairments
Galantamine showed no clear difference in serious adverse events (excluding deaths) at 26 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at 4 weeks; 1085 participants (8 RCTs) · cervical dystonia
Botulinum toxin type A probably leads to higher adverse events at 4 weeks; 1085 participants (8 RCTs) compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.23 [1.05, 1.43]
Studies not reported
Moderate
Specific adverse events · women with PMS
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes specific adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
206 participants
Very low
Incidence of adverse events within 30 days of surgery · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Withdrawal due to serious adverse events Not reported · patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: serious adverse events ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events (AEs; adverse drug reaction): asystole · patients with acute myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): asystole compared with placebo or no intervention (very low certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ children · patients with chronic asthma
Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ children compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants with any serious adverse events · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Average number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review